GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution
Journal
Annals of Hematology
Journal Volume
94
Journal Issue
2
Pages
211-221
Date Issued
2015
Author(s)
Kuo Y.-Y.
Liu C.-Y.
Tseng M.-H.
Huang C.-F.
Chiang Y.-C.
Liu M.-C.
Liu C.-W.
Abstract
Recently, mutations of the GATA binding protein 2 (GATA2) gene were identified in acute myeloid leukemia (AML) patients with CEBPA double mutations (CEBPAdouble-mut), but the interaction of this mutation with other genetic alterations and its dynamic changes during disease progression remain to be determined. In this study, 14 different missense GATA2 mutations, which were all clustered in the highly conserved N-terminal zinc finger 1 domain, were identified in 27.4, 6.7, and 1?% of patients with CEBPAdouble-mut, CEBPAsingle-mut, and CEBPA wild type, respectively. All but one patient with GATA2 mutation had concurrent CEBPA mutation. GATA2 mutations were closely associated with younger age, FAB M1 subtype, intermediate-risk cytogenetics, expression of HLA-DR, CD7, CD15, or CD34 on leukemic cells, and CEBPA mutation, but negatively associated with FAB M4 subtype, favorable-risk cytogenetics, and NPM1 mutation. Patients with GATA2 mutation had significantly better overall survival and relapse-free survival than those without GATA2 mutation. Sequential analysis showed that the original GATA2 mutations might be lost during disease progression in GATA2-mutated patients, while novel GATA2 mutations might be acquired at relapse in GATA2-wild patients. In conclusion, AML patients with GATA2 mutations had distinct clinic-biological features and a favorable prognosis. GATA2 mutations might be lost or acquired at disease progression, implying that it was a second hit in the leukemogenesis of AML, especially those with CEBPA mutation. ? 2014, Springer-Verlag Berlin Heidelberg.
SDGs
Other Subjects
antineoplastic agent; CCAAT enhancer binding protein alpha; CD15 antigen; CD34 antigen; CD7 antigen; HLA DR antigen; transcription factor GATA 2; CCAAT enhancer binding protein; CEBPA protein, human; GATA2 protein, human; transcription factor GATA 2; acute myeloblastic leukemia; adult; age distribution; aged; amino terminal sequence; antigen expression; Article; cancer chemotherapy; cancer patient; cancer recurrence; cancer risk; cancer survival; chromosome aberration; controlled study; cytogenetics; disease course; exon; female; follow up; GATA2 gene; gene; genetic risk; human; human cell; induction chemotherapy; karyotype; leukemia cell; leukemia remission; leukemogenesis; major clinical study; male; middle aged; missense mutation; mutational analysis; overall survival; priority journal; recurrence free survival; recurrence risk; risk assessment; sequential analysis; survival rate; treatment response; young adult; zinc finger motif; acute disease; adolescent; genetics; genotype; Kaplan Meier method; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; mutation; pathology; prognosis; tumor recurrence; very elderly; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; CCAAT-Enhancer-Binding Proteins; Chromosome Aberrations; Disease Progression; Follow-Up Studies; GATA2 Transcription Factor; Genotype; Humans; Kaplan-Meier Estimate; Karyotype; Leukemia, Erythroblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Young Adult
Type
journal article